Group Pharmaceuticals Latest Annual Report, Balance Sheet and Financials

Group Pharmaceuticals Limited Standalone Balance Sheet (Rs. In Lakhs)

Particular	31-03-2025	31-03-2024
Shareholders’ funds
Share capital	253.68	253.68
Reserves and surplus	6,567.39	5,523.84
Non-current liabilities
Long term provisions	108.63	73.09
Deferred tax liability-(net)	9.61	3.23
Current liabilities
Due to micro and small enterprise	271.13	304.54
Due to others	487.13	421.71
Other current liabilities	615.47	640.11
Short term provisions	23.19	48.50
Total Equity and Liabilities	8,336.22	7,268.70
Non-current assets
Property, plant and equipment	1,398.38	1,419.22
Intangible assets	4.80	5.23
Non-current investments	1,102.17	298.00
Long term loans and advances	65.34	63.70
Current assets
Inventories	1,220.78	840.21
Trade receivables	2,820.82	2,860.26
Cash and bank balances	1,350.95	1371.02
Short term loan and advances	329.96	398.69
Other current assets	43.02	12.37
Total Assets	8,336.22	7,268.70

Group Pharmaceuticals Limited Standalone Profit & Loss (Rs. In Lakhs)

Particulars	31-03-2025	31-03-2024
Revenue from operations	16,478.50	15,072.17
Revenue from job work	130.71	94.81
Other Income	221.84	152.71
Total income	16,831.05	15,319.69
Expenses
Cost of materials consumed	5,560.48	5,288.83
Purchase of stock in trade	843.63	1,036.18
Changes in inventories of finished goods, work-in-Progress and stock-in-trade	(73.58)	84.74
Employee benefits and expenses	4,843.20	4,016.07
Finance costs	20.13	25.63
Depreciation and amortization expenses	170.39	188.78
Other expenses	4,079.04	3,327.89
Total expenses	15,443.28	13,968.12
Profit /(Loss) before exceptional and extraordinary items and tax	1,387.77	1,351.57
Profit after exceptional and extraordinary items and before tax	1,387.77	1,351.57
Current tax	340.30	345.00
Deferred tax	6.36	27.21
Short/(Excess) Provision for earlier years	(2.44)	(16.36)
Profit for the Year	1,043.55	995.72
Earnings per equity share: Basic	41.14	39.25

Group Pharmaceuticals Limited Standalone Cash Flow Statement (Rs. In Lakhs)

Particular	31-03-2025	31-03-2024
Cash Flow From Operating Activities
Profit before tax	1,387.77	1,351.57
Adjustments for:
Finance costs	20.13	25.63
Depreciation and amortisation	170.39	188.78
Provision for doubtful debts	(0.03)	1.83
Gain on sale of Property Plant and Equipment	-	6.71
Operating Profit before Working Capital Changes	1,578.26	1,574.52
Adjustments for:
(Increase)/Decrease in Inventories	(380.57)	288.27
(Increase)/Decrease in Sundry Debtors	39.47	(627.88)
(Increase) /Decrease in Loans & Advances and Other Current Asset	8.59	(69.08)
Increase /(Decrease) in Trade Payables	32.01	148.32
Increase in provision	10.23	(128.21)
Decrease /(Increase) in Other Current Liabilities	(24.65)	127.60
Cash generated from operations	1,263.34	1313.53
Direct Taxes Paid (net of refund)	(310.00)	(309.71)
Net Cash from Operating Activities	953.34	1003.82
Cash Flow From Investing Activities
Purchase of fixed assets	(149.12)	(72.21)
(Increase)/decrease in investment	(804.17)	(50.00)
Other balance with banks	(268.49)	(740.62)
Net Cash Surplus / (Used) in Investing Activities	(1,221.78)	(862.83)
Cash Flow From Financing Activities
Proposed Dividend	-	(50.74)
Interest and other finance cost paid	(20.13)	(25.63)
Net Cash Surplus /(used) in Financing Activities	(20.13)	(76.37)
Net Change In Cash And Cash Equivalents	(288.57)	64.62
Opening balance of cash and cash equivalents	386.73	322.11
Closing balance of cash and cash equivalents	98.16	386.73

Summary of the Cash Flow Statement for the years 2025 and 2024

Operating Activities

The company generated a net operating cash inflow of ₹953 lakh in FY25, slightly lower than ₹1,004 lakh in FY24. Profit before tax remained stable at ₹1,388 lakh compared to ₹1,352 lakh in the previous year, supported by non-cash charges like depreciation (₹170 lakh) and finance costs (₹20 lakh). However, working capital changes dragged operating cash: inventories increased by ₹381 lakh in FY25 (vs. a release of ₹288 lakh in FY24), and other liabilities fell. On the positive side, debtors decreased by ₹39 lakh compared to a sharp increase in FY24, which provided some relief. Overall, operating cash generation remains strong but showed a marginal decline due to higher inventory build-up.

Investing Activities

Net cash outflow from investing activities rose to ₹1,222 lakh in FY25 against ₹863 lakh in FY24, reflecting a significant increase in investments (₹804 lakh vs. only ₹50 lakh earlier). Capital expenditure also rose moderately to ₹149 lakh from ₹72 lakh, while balances kept with banks reduced liquidity by another ₹268 lakh. This indicates that the company is channelling more funds into long-term investments, leading to higher cash absorption.

Financing Activities

Cash used in financing activities was ₹20 lakh in FY25, a reduction compared to ₹76 lakh in FY24. This mainly represents interest payments, as no dividend was declared in FY25 (unlike ₹51 lakh in FY24). The decline in financing outflows suggests tighter cost control, though it also reflects the absence of shareholder payouts.

Net Change In Cash And Cash Equivalents

The company reported a net decrease in cash of ₹289 lakh in FY25, reversing the positive addition of ₹65 lakh in FY24. Consequently, closing cash and cash equivalents fell sharply to ₹98 lakh in FY25 from ₹387 lakh in FY24. While operating performance is stable, the heavy outflow towards investments has strained liquidity.

Group Pharmaceuticals Limited Standalone Financial Ratios

Particular	31-03-2025	31-03-2024
Current Ratio (in times)	4.13	3.87
Debt Service Coverage Ratio (in times)	125.08	124.29
Return on Equity Ratio (in %)	16.57%	18.77%
Trade receivables turnover Ratio (in times)	6.03	5.95
Trade payable turnover Ratio (in times)	8.14	9.39
Net Capital Turnover Ratio (in times)	3.80	3.73
Net Profit Ratio (in %)	6.20%	6.50%
Return on Capital Employed Ratio (in %)	20.18%	23.30%
Return on investment (in %)	7.77%	13.99%

Summary of the financial ratio for the years 2025 and 2024

Current Ratio 

FY25: 4.13 | FY24: 3.87
The current ratio is well above the benchmark of 1–2, indicating very strong short-term liquidity. The slight improvement shows the company has more than sufficient current assets to cover current liabilities, though excessively high liquidity may also imply under-utilisation of resources.

Debt Service Coverage Ratio 

FY25: 125.08 | FY24: 124.29
The DSCR is exceptionally high, showing the company has ample operating earnings to cover debt obligations many times over. This reflects negligible risk of default and a very strong debt repayment capacity.

Return on Equity 

FY25: 16.57% | FY24: 18.77%
ROE has declined slightly, indicating a lower return generated on shareholders’ funds. While still strong and well above average, the downward movement suggests profitability relative to equity has weakened marginally.

Trade Receivables Turnover Ratio

FY25: 6.03 | FY24: 5.95
The ratio improved a little, showing receivables are being collected more quickly. This strengthens cash flow and reflects stable collection efficiency.

Trade Payables Turnover Ratio 

FY25: 8.14 | FY24: 9.39
The ratio fell, suggesting the company is taking a slightly longer time to pay its suppliers. While this can help preserve cash, it may affect supplier relationships if extended too much.

Net Capital Turnover Ratio

FY25: 3.80 | FY24: 3.73
A small improvement indicates that the company is using its working capital more effectively to generate sales. This reflects stable operational efficiency.

Net Profit Ratio

FY25: 6.20% | FY24: 6.50%
The margin declined slightly, showing that a smaller portion of revenue is being converted into profit. Cost pressures or pricing issues could be the reason behind this dip.

Return on Capital Employed 

FY25: 20.18% | FY24: 23.30%
The ratio has declined, suggesting that the company is generating lower returns from its total capital base. While still healthy, this reduction signals a dip in efficiency of capital utilization.

Return on Investment 

FY25: 7.77% | FY24: 13.99%
ROI dropped sharply, indicating weaker performance of investments compared to the previous year. This may be due to reduced gains from financial investments or lower returns from deployed capital.